Optometry’s role in the opioid epidemic

Article

I have heard doctors of various specialties refer to their Drug Enforcement Agency (DEA) license fees as no more than taxes and prescription drug monitoring programs as government overreach. It is true that when my DEA license is about to expire, I wish the renewal fee was a few hundred dollars less. However, I do realize all that goes into my privilege to judiciously prescribe controlled substances for acute pain to the eye and adnexa.

Related: 3 points to consider when prescribing narcotics

As for prescription drug monitoring programs, ODs in Georgia with DEA licenses had to register by January 2019, and I could not agree more that these programs are necessary and even essential to curb drug overdoses in the U.S.

CDC report
In December 2018, the Centers for Disease Control and Prevention (CDC) published a report on drug overdose deaths in the U.S. between 2011 and 20161 which contained, among other metrics, the most common drugs involved.

Previously by Dr. Casella: Make one decision per week to improve the practice

Not surprisingly, fentanyl, a synthetic opioid indicated for severe pain, was at the top of the list by being referenced in the death certificates of 28.8 percent of drug overdose deaths. Heroin and cocaine rounded out the top three, respectively.

ODs should have vested interest in these data, at the very least from the perspective of a concerned citizen. However, as the list of drugs continues, drugs that are commonly prescribed for acute eye pain are listed.

Hydrocodone ranks ninth on the list, referenced in 5 percent of drug overdose deaths in 2016. When a narcotic analgesic is indicated, hydrocodone is a drug of choice for many ODs. It is relatively cheap and readily available in fixed combination with non-narcotic analgesics. It also works quite well at controlling severe pain, say, from a geographic corneal abrasion.

Rxing hydrocodone
In fact, hydrocodone is so popular in primary eye care that, when it was moved from Schedule 3 to Schedule 2 by the FDA several years ago, numerous state optometry associations passed so-called “hydrocodone fix” legislation (Georgia included). These laws allowed ODs to continue prescribing hydrocodone in states in which Schedule 2 drugs were not on their formularies.

Read more Optometry Times editorials here

I encourage everyone to read the report. I teach a continuing education course on drug diversion, and I have incorporated these data into my curriculum. As more data becomes available, the hope is that the statistics from the CDC will show a steep curbing of the drug overdose epidemic in the U.S.

The prescribing of such medications is an earned privilege, and with it comes a seat at a table that is currently charged with the task of curbing the epidemic of drug overdose.

Read more by Dr. Casella

References:

1. Hedegaard HH, Bastian, BA, Trinidad JP, Spencer M, Warner, M. Drugs Most Frequently Involved in Drug Overdose Deaths: United States, 2011–2016. National Vital Statistics Reports. 2018 Dec;67(9). Available at: https://www.cdc.gov/nchs/data/nvsr/nvsr67/nvsr67_09-508.pdf. Accessed 1/11/19.

Recent Videos
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
Clark Chang, OD, MSA, MSc, FAAO, discussed the complexities of diagnosing keratoconus in his Rapid Fire presentation given at the American Academy of Optometry 2024 meeting.
Mohammad Rafieetary, OD, FAAO, FORS, Dipl ABO, ABCMO, details the ease of genetic testing when diagnosing patients or reassessing a patient's diagnosis.
Gromacki, OD, FAAO, FSLS, emphasizes that corneal GP lenses remain an important part of a contact lens specialist's armamentarium
© 2024 MJH Life Sciences

All rights reserved.